Executive Order Signed: Cannabis Moving to Schedule III

President Trump’s December 18th executive order has officially set the wheels in motion for cannabis to move from Schedule I to Schedule III, and if you’re not already preparing your business for what’s coming next, you’re already behind.

Here’s what we’re covering today:

• The real impact of rescheduling (spoiler: it’s not immediate, but it’s massive)
• 280E tax relief breakdown and what it means for your bottom line
• Financial services access that could change everything
• 2026 compliance requirements you need to start planning for now
• Action steps every cannabis business should take immediately

Let me be direct with you: This isn’t just another regulatory update you can file away and forget about. This executive order is the starting gun for the most significant transformation our industry has seen since legalization began. And the businesses that prepare now will have a real competitive advantage over those who wait.

What the Executive Order Actually Does (And Doesn’t Do)

Let’s cut through the hype and get to the facts. Trump’s executive order doesn’t magically reschedule cannabis overnight. What it does is direct the Department of Justice to expedite the completion of the rulemaking process that’s already underway.

Think of it this way: if the rescheduling process was a highway construction project that’s been dragging on for years, this executive order just brought in extra crews and told them to work around the clock to finish the job.

Here’s the timeline you need to understand:

• October 2022: Biden initiated the review process
• August 2023: HHS recommended Schedule III classification
• May 2024: DEA proposed the formal rule
• December 2025: Trump’s executive order demands completion
• April 28, 2026: State-licensed medical cannabis moved to Schedule III (the order is being challenged in court); adult-use cannabis remains in Schedule I while the DEA’s administrative hearing continues

For the latest on each step, see our Cannabis Rescheduling Tracker.

280E Relief: What Changes, and for Whom

Here’s where things get really interesting for your cannabis accounting strategy. Section 280E has been the silent killer of cannabis business profitability since day one, preventing you from deducting ordinary business expenses that every other industry takes for granted.

Under Schedule I, you can only deduct cost of goods sold. That’s it. No marketing expenses, no rent, no salaries for non-production staff, no professional services. Nothing.

Under Schedule III, those restrictions disappear for the activity that has moved. Today that means state-licensed medical activity, with an open question: the IRS has not said whether relief depends on DEA registration, and the DEA has so far registered only dispensaries in medical-only states. For operators with both medical and adult-use licenses, whether the medical side is outside 280E is unresolved. Adult-use cannabis is still in Schedule I, so 280E still applies to adult-use activity until that changes.

Let me put this in perspective with an illustrative example. Say you’re running a medical-only dispensary with $2 million in annual revenue, $1.2 million of cost of goods sold and $600,000 of other operating expenses. Your actual cash-flow profit is $200,000, but under 280E you pay tax on $800,000, because the $600,000 of operating expenses can’t be deducted.

Illustrative only, not a projection for any business. The math: $2,000,000 − $1,200,000 = $800,000 taxable under 280E; deducting the $600,000 of operating expenses leaves $200,000. Each figure × 21%. It ignores state taxes and assumes a C corporation; pass-through entities are taxed at the owners’ rates. Results vary.

Under 280E, federal tax would take $168,000 of a $200,000 cash profit. If that activity is outside 280E, you pay tax on the actual $200,000 profit.

That’s not just tax relief: that’s a complete transformation of your business economics.

For cannabis fractional CFO professionals like us, this means helping our clients restructure their financial operations. The accounting methods that made sense under 280E won’t just be unnecessary; they could actually hurt you if you don’t adapt.

Financial Services: Slow, Uneven Change

Rescheduling on its own does not change federal banking rules. Over time, Schedule III status for medical activity may make some lenders, processors and insurers more willing to serve the industry, but nothing here is automatic. The services operators most want include:

• Traditional business loans
• Credit lines for inventory and expansion
• Payment processing without cannabis-specific surcharges
• Investment opportunities previously off-limits
• Insurance products designed for legitimate businesses, not gray-market operators

I’ve been working with cannabis businesses for years, and I can tell you that the financial services restrictions have been more than an inconvenience. They’ve been a strategic constraint that’s forced suboptimal business decisions across the board.

But here’s the catch: not every bank is going to jump in immediately. The smart money is on building relationships with forward-thinking financial institutions now, before the rush hits.

2026 Compliance: New Rules, New Requirements, New Opportunities

While everyone’s celebrating the benefits of rescheduling, cannabis compliance professionals are already looking ahead to the regulatory adjustments coming in 2026.

Here’s what we expect:

• Federal quality standards that go beyond current state requirements
• Interstate commerce regulations as barriers between states start falling
• Revised safety protocols aligned with other Schedule III substances
• New reporting requirements for federal oversight
• Updated licensing frameworks that bridge federal and state systems

The businesses that start preparing for these changes now, rather than scrambling to catch up later, will have a real competitive advantage.

Think of it this way: every major regulatory shift creates winners and losers. The winners are usually the ones who saw it coming and prepared accordingly.

What Every Cannabis Business Should Do Right Now

Stop waiting. Start preparing. Here’s your immediate action plan:

1. 1

   Audit Your Current Accounting Structure

   Review every aspect of your cannabis accounting practices. What works under 280E might be completely wrong for a Schedule III world. If you sell both medical and adult-use, your books now need to separate the two so they are ready whichever way the IRS rules, while your estimated payments still assume 280E may apply.

2. 2

   Document Everything

   Start maintaining detailed records of all business expenses, not just COGS. When 280E relief reaches your activity, you’ll want the records to support your deductions.

3. 3

   Review Your Tax Strategy

   Work with cannabis tax advisory professionals to model different scenarios. What does your tax liability look like for medical activity now, and for adult-use activity if and when it moves? How should you time major expenses or investments?

4. 4

   Strengthen Financial Relationships

   Begin conversations with banks and financial institutions about future services. Don’t wait until everyone else is lining up for the same opportunities.

5. 5

   Plan for Compliance Changes

   Start reviewing your standard operating procedures against what federal oversight might require. Better to over-prepare than scramble later.

The Strategic Advantage: Why Acting Now Matters

Let me share something I’ve learned from working with cannabis businesses: the biggest opportunities always go to the companies that move first.

When adult-use markets opened in various states, the operators who had their applications ready, their funding secured, and their teams in place before legalization hit were the ones who captured market share. The same principle applies here.

Rescheduling isn’t just a regulatory change; it’s a competitive reset. Your current advantages might evaporate, but new ones are about to emerge. The question is whether you’ll be positioned to capitalize on them.

Related Reading

• Current status, medical and adult-use: Cannabis Rescheduling Tracker
• What the medical/adult-use split means for your books: The Bifurcation Is Official: 280E Relief for Medical Cannabis
• Step-by-step preparation: How to Prepare Your Cannabis Accounting for Schedule III Rescheduling
• 2026 M&A outlook: Why 2026 Will Be a Big Year for Cannabis M&A

How Buds Group Can Help You Navigate This Transition

This is exactly why Buds Group exists. We’ve been helping cannabis businesses navigate complex regulatory and financial challenges since the beginning, and we’re deep in the work of the post-rescheduling world.

Our approach is comprehensive:

• Financial restructuring for the new tax environment
• Compliance planning for anticipated federal requirements
• Strategic positioning to take advantage of new opportunities
• Risk management to protect against transition challenges

We’re not just cannabis consultants. We’re strategic partners who understand that your success in the next phase of this industry depends on the decisions you make today.

The executive order has been signed. The countdown has begun. The only question left is whether you’ll be ready.

Ready to position your cannabis business for the post-280E world? Book a free 280E review to see how our fractional CFO and advisory work can help you navigate this historic transition. In an industry this dynamic, standing still is moving backwards.